These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 12385006)

  • 1. Mutation analysis and mRNA expression of trail-receptors in human breast cancer.
    Seitz S; Wassmuth P; Fischer J; Nothnagel A; Jandrig B; Schlag PM; Scherneck S
    Int J Cancer; 2002 Nov; 102(2):117-28. PubMed ID: 12385006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers.
    Shin MS; Kim HS; Lee SH; Park WS; Kim SY; Park JY; Lee JH; Lee SK; Lee SN; Jung SS; Han JY; Kim H; Lee JY; Yoo NJ
    Cancer Res; 2001 Jul; 61(13):4942-6. PubMed ID: 11431320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma.
    Lee SH; Shin MS; Kim HS; Lee HK; Park WS; Kim SY; Lee JH; Han SY; Park JY; Oh RR; Kang CS; Kim KM; Jang JJ; Nam SW; Lee JY; Yoo NJ
    Oncogene; 2001 Jan; 20(3):399-403. PubMed ID: 11313970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer.
    McCarthy MM; Sznol M; DiVito KA; Camp RL; Rimm DL; Kluger HM
    Clin Cancer Res; 2005 Jul; 11(14):5188-94. PubMed ID: 16033835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers.
    Lee SH; Shin MS; Kim HS; Lee HK; Park WS; Kim SY; Lee JH; Han SY; Park JY; Oh RR; Jang JJ; Han JY; Lee JY; Yoo NJ
    Cancer Res; 1999 Nov; 59(22):5683-6. PubMed ID: 10582684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of gene mutation in TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2) in chronic myelogenous leukemia and myelodysplastic syndrome, and analysis of mRNA Expressions of TRAIL and TRAIL-related genes in chronic myelogenous leukemia.
    Liu LG; Tanaka H; Ito K; Ito T; Sultana TA; Kyo T; Kimura A
    Acta Haematol; 2005; 113(2):113-23. PubMed ID: 15802890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity.
    Adams J; Cuthbert-Heavens D; Bass S; Knowles MA
    Cancer Lett; 2005 Apr; 220(2):137-44. PubMed ID: 15766588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive expression analysis of TNF-related apoptosis-inducing ligand and its receptors in colorectal cancer: Correlation with MAPK alterations and clinicopathological associations.
    Tsikalakis S; Chatziandreou I; Michalopoulos NV; Theodoropoulos GE; Sakellariou S; Korkolopoulou P; Patsouris E; Saetta AA
    Pathol Res Pract; 2018 Jun; 214(6):826-834. PubMed ID: 29731264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.
    Rubio-Moscardo F; Blesa D; Mestre C; Siebert R; Balasas T; Benito A; Rosenwald A; Climent J; Martinez JI; Schilhabel M; Karran EL; Gesk S; Esteller M; deLeeuw R; Staudt LM; Fernandez-Luna JL; Pinkel D; Dyer MJ; Martinez-Climent JA
    Blood; 2005 Nov; 106(9):3214-22. PubMed ID: 16051735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer.
    Wu WG; Soria JC; Wang L; Kemp BL; Mao L
    Anticancer Res; 2000; 20(6B):4525-9. PubMed ID: 11205299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma.
    Jeng YM; Hsu HC
    Cancer Lett; 2002 Jul; 181(2):205-8. PubMed ID: 12175536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
    Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.
    Ganten TM; Sykora J; Koschny R; Batke E; Aulmann S; Mansmann U; Stremmel W; Sinn HP; Walczak H
    J Mol Med (Berl); 2009 Oct; 87(10):995-1007. PubMed ID: 19680616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y; Zhang B
    Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TRAIL-receptor-1: TRAIL-receptor-3 and -4 ratio is a predictor for TRAIL sensitivity of cancer cells.
    Büneker C; Mohr A; Zwacka RM
    Oncol Rep; 2009 May; 21(5):1289-95. PubMed ID: 19360306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter.
    Sträter J; Hinz U; Walczak H; Mechtersheimer G; Koretz K; Herfarth C; Möller P; Lehnert T
    Clin Cancer Res; 2002 Dec; 8(12):3734-40. PubMed ID: 12473583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheumatoid arthritis synovial fluid macrophages express decreased tumor necrosis factor-related apoptosis-inducing ligand R2 and increased decoy receptor tumor necrosis factor-related apoptosis-inducing ligand R3.
    Perlman H; Nguyen N; Liu H; Eslick J; Esser S; Walsh K; Moore TL; Pope RM
    Arthritis Rheum; 2003 Nov; 48(11):3096-101. PubMed ID: 14613271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of DLC-1 expression in human breast cancer.
    Plaumann M; Seitz S; Frege R; Estevez-Schwarz L; Scherneck S
    J Cancer Res Clin Oncol; 2003 Jun; 129(6):349-54. PubMed ID: 12759748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
    Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
    Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site.
    Ruiz de Almodóvar C; Ruiz-Ruiz C; Rodríguez A; Ortiz-Ferrón G; Redondo JM; López-Rivas A
    J Biol Chem; 2004 Feb; 279(6):4093-101. PubMed ID: 14623878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.